Update on the Current Status and Indications for Transcatheter Edge-to-Edge Mitral Valve Repair

被引:0
作者
Mohammed Qintar
Adnan K. Chhatriwalla
机构
[1] Henry Ford Health System,Center for Structural Heart Disease, Division of Cardiology
[2] Saint Luke’s Mid America Heart Institute and University of Missouri-Kansas City,undefined
来源
Current Cardiology Reports | 2020年 / 22卷
关键词
Transcatheter edge-to-edge mitral valve repair; MitraClip; Indications; Mitral valve regurgitation;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 223 条
[1]  
Enriquez-Sarano M(2009)Mitral regurgitation Lancet 373 1382-1394
[2]  
Akins CW(2006)Burden of valvular heart diseases: a population-based study Lancet 368 1005-1011
[3]  
Vahanian A(2016)Mitral valve disease--current management and future challenges Lancet 387 1324-1334
[4]  
Nkomo VT(2017)2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force On Clinical Practice Guidelines J Am Coll Cardiol 70 252-289
[5]  
Gardin JM(2014)2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Thorac Cardiovasc Surg 148 e1-e132
[6]  
Skelton TN(2007)What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J 28 1358-1365
[7]  
Gottdiener JS(2011)Percutaneous repair or surgery for mitral regurgitation N Engl J Med 364 1395-1406
[8]  
Scott CG(2015)Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II J Am Coll Cardiol 66 2844-2854
[9]  
Enriquez-Sarano M(2013)The EVEREST II realism continued access study: effectiveness of transcatheter reduction of significant mitral regurgitation in surgical candidates J Am Coll Cardiol 61 E1959-181
[10]  
Nishimura RA(2014)Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study J Am Coll Cardiol 64 172-139